Project Grant R43TR006062
Award Date 7/1/26
Completion Date 6/30/27
Dollars Obligated $311K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Lebanon, NH 03766, USA
Similar Awards
- FEDERAL GRANT AWARD SUMMARY Cincinnati Children's Hospital Medical Center received a $803,958 Project Grant award (announced July 23, 2025) from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The award supports research and development of an innovative nanocarrier-based therapeutic delivery system designed to treat neuronopathic Gaucher disease (NGD), a severe...
- Federal Grant Award Summary Neucore Bio, Inc. received a $350,000 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded on August 15, 2025, with a completion date of August 14, 2026. The award funds development of the Fibroblast-Derived Engineered Extracellular Vesicle (FiEEV) platform technology for RNA therapeutic delivery to treat Charcot-Marie-Tooth Disease Type 1A (CMT1A), a rare genetic neuromuscular disorder affecting approximately 1 in...
- Federal Grant Award Summary Gentibio, Inc. was awarded $825,756 by the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) beginning May 1, 2026, with a completion date of June 30, 2028. The project, titled "Tissue-Engineered Tregs for the Treatment of Amyotrophic Lateral Sclerosis," supports advanced biomedical research aimed at developing innovative therapeutic solutions for neurodegenerative disease. The award funds hypothesis-driven...
- Federal Grant Award Summary Cisterna Biologics, Inc. received a $349,746 Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350, effective August 1, 2025, with a completion date of July 31, 2027. This Phase I Small Business Innovation Research (SBIR) award supports the development and validation of an innovative mRNA purification platform designed to eliminate length-related impurities, including double-stranded RNA (dsRNA), long RNA (lRNA),...
- Federal Project Grant Award Summary Tega Therapeutics Inc. received a $1.0M Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective August 5, 2025, with completion targeted for July 31, 2026. The award funds research to identify and validate clinical biomarkers for GM1 gangliosidosis, a lysosomal storage disease characterized by deficiency...
- Federal Grant Award Summary Cellfe, Inc. received a Phase I Small Business Innovation Research (SBIR) grant of $314,000 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) for the period of September 1, 2025 through August 31, 2026. The company will conduct proof-of-concept research and development to optimize and validate the CellFE platform, a microfluidic transfection technology designed to enable...
- Federal Grant Award Summary Capienda Biotech, LLC received a $329,272 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded August 1, 2025, with completion expected January 31, 2027. The company is developing an innovative high-throughput kinetic screening instrument to accelerate small-molecule drug discovery targeting kinase enzymes. Building on a prior NSF Small Business Innovation Research Phase I prototype capable of 128 simultaneous tests,...
- Federal Project Grant Award Summary The National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded $168,000 to Icahn School of Medicine at Mount Sinai, effective July 1, 2026 through June 30, 2027, to investigate the role of the INTS12 protein in transcription elongation control during human red blood cell development and in Congenital Dyserythropoietic Anemia Type IV (CDA IV), a rare hemolytic anemia affecting children. The project will utilize the newly established BEL-A...
- Federal Project Grant Award Summary Award Details: On August 1, 2025, the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded Cila Therapeutics Inc. a Project Grant of $379,948 to develop CIL-0X, a novel platform technology designed to enhance the delivery of inhaled ribonucleic acid (RNA) therapeutics to lung cells. The 18-month project, concluding January 31, 2027, will be performed at the company's Jamaica Plain, Massachusetts facility. Products and Services:...
- Federal Grant Award Summary Nostopharma LLC received a $815,584 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, effective July 3, 2025 through June 30, 2027. The award funds preclinical proof-of-concept research for a novel localized drug delivery treatment addressing Fibrodysplasia Ossificans Progressiva (FOP), an ultrarare genetic disease affecting approximately 1 in 1.5-2.0 million live births. The primary deliverable is the...